Pehea e hoʻouna ai i nā Peptides i hoʻolālā ʻia e AI i kahi CDMO: Handoff Playbook
Papa helu

Pane wikiwiki

Master AI peptide CDMO submission with metadata standards, pre-synthesis i loko o nā kānana silico, and de-risking protocols from the GenScript-Tamarind deal.

Pehea e hoʻouna ai i nā Peptides i hoʻolālā ʻia e AI i kahi CDMO: Handoff Playbook

Ua hoʻololi maoli ka naʻauao hana hoʻomohala i ka ʻike de novo peptide. ʻO nā papa hana hoʻonaʻauao hohonu—mai RFdiffusion a me ProteinMPNN a i AlphaFold3 a me ESM3—ke hana nei i kēia manawa he ʻumi kaukani o nā kaʻina hoʻopaʻa moho i nā minuke.. Eia naʻe, hoʻoweliweli ka bottleneck hoʻomau i nā pipeline ʻike lāʻau helu helu: ka AI-i-paʻa lima.

Pehea e hoʻouna ai i nā Peptides i hoʻolālā ʻia e AI i kahi CDMO: Handoff Playbook

Hoʻohālikelike ke kumu hoʻohālikelike i kahi peptide e ka geometry iwi kuamoʻo, wanana paa ikaika, a me ka hilinaʻi kūkulu. He Hui Hoʻolālā a me ka Hana Hana Hana (CDMO), ma ke ʻano like ʻole, loiloi i kēlā kaʻina like e ke kemika pae paʻa, hiki ke hoʻoheheʻe, pale i nā kinetics hui, a me ka hoomaemae ana. Ke hoʻoili ʻia nā hits computational i kahi CDMO ma ke ʻano he kaula kikokikona FASTA maʻalahi me ka ʻole o ka pōʻaiapili kino, piʻi nui ka helu ʻana o ka synthesis.

ʻO ka mea i hala iho nei ʻO ka hui pū ʻana o GenScript a me Tamarind Bio hōʻike i ka hoʻololi ʻoihana nui: ka hoʻopili pololei ʻana i nā paepae hoʻolālā AI e pili ana i ke ao i nā lawelawe hōʻoia wet-lab. ʻO ka hoʻohui ʻana i kā Tamarind Bio o nā hiʻohiʻona hoʻolālā molecular i loko o ka Tamarind Assay Portal me nā mana hana automated o GenScript e hoʻokumu i kahi mua no nā kahe hana kikohoʻe-a-kino..

Pehea e hoʻouna ai i nā Peptides i hoʻolālā ʻia e AI i kahi CDMO: Handoff Playbook

No ka hoʻonui ʻana i kēia hoʻohui ʻakomi, biotech R&D nā hui, nā mea noiʻi nui, a me nā mea hoʻomaʻamaʻa kaʻina hana e koi i kahi protocol hoʻouna maʻamau. Hōʻike kēia puke pāʻani i nā koi ʻenehana, pre-synthesis i loko o nā kānana silico, ka hoʻohaʻahaʻa ʻana i ke ʻano hana ʻole, a me nā hōʻoia hōʻoia e pono ai e hoʻopau i ka pilikia AI-designed peptide sequence handoffs i nā hoa CDMO.


1. Ma waho aʻe o ka faila FASTA: ʻO ka metadata hoʻouna CDMO pono

Hoʻouna i kahi kaula amino acid maʻalahi (e.g., ACDEFGHIKLMNPQRSTVWY) i kahi CDMO ke kumu nui o ka lohi o ka synthesis a me nā hemahema analytical i manaʻo ʻole ʻia. Hoʻokomo pinepine nā kumu hoʻohālike i nā topologies iwi kuamoʻo maʻamau, nā ʻāpana hydrophobic mānoanoa, a i ʻole ka hoʻohui ʻana i ka disulfide ʻaʻole ia e like me ka synthesis peptide solid-phase maʻamau (SPSS) ʻAʻole hiki i nā protocols ke hana maʻalahi.

No ka hoʻopaʻa pono ʻana i ka unuhi kemika, pono e loaʻa i ka pūʻolo hoʻouna piha ʻehā mau pou metadata ʻokoʻa.

Pehea e hoʻouna ai i nā Peptides i hoʻolālā ʻia e AI i kahi CDMO: Handoff Playbook

AI Hoʻolālā Hua (PDB / JSON)

  1. Hoʻolālā Hoʻokumu & Hōʻike Hoʻohālike (Hoʻolālā hoʻohālike, hua, pLDDT, pAE)
  2. Helu helu helu helu (Hoʻopaʻa ΔG, ANO, Ka ikehu hoʻonā)
  3. Kemika & Nā Paʻa Hana (Kāpena N/C, Kaʻikala, Non-canonical AA)
  4. Kūlana Kūlana & Hoʻohana i ka hihia (Maʻemaʻe ≥98%, Ka nui, ʻO nā koi sterile) Puke kauoha hana CDMO maʻamau

Pills 1: Hoʻolālā Hoʻokumu a me Generative Context

Pono nā ʻenekini synthesis CDMO e hoʻomaopopo i ka hana ʻana o ke kaʻina. Hōʻike ka hōʻike kumu hoʻohālike i nā manaʻo hoʻolālā intrinsic:

  • Hoʻohālike Hoʻohālike a me ka Version: E wehewehe mai ka RFdiffusion mai ke kaʻina, AlphaFold-Multimer, PolokinaMPNN, ESMFold, a i ʻole he ʻano hoʻohālike.
  • Nā ʻāpana hana: E hoʻopaʻa i nā helu hua maʻamau, hoʻonohonoho mahana, a me nā manaʻo hoʻolālā (e.g., hoʻopili ʻia me ka hydrophobic interface).
  • Nā helu hilinaʻi no kēlā me kēia koena: E hoʻokomo i ka pLDDT kūloko (wānana ʻia ka hoʻāʻo ʻokoʻa kūloko kūloko) nā helu ma ke kaʻina. He kaʻina me nā wahi pLDDT haʻahaʻa (< 70) pili pinepine i nā puka lou maʻalahi a i ʻole nā ​​ʻāpana i wehe ʻia e hana hewa ʻole i ka wā hoʻomaʻemaʻe.

Pills 2: Helu helu helu helu

  • Kuhi ʻia i kuhi ʻia (pAE): Hāʻawi i nā waiwai pAE no nā peptides paʻa i ka pahuhopu e hōʻike i nā koena pili koʻikoʻi.
  • Hoʻopaʻa i ka ikehu manuahi (ΔG): E hoʻokomo i nā helu kikowaena electrostatic a me van der Waals.
  • Wehewehe i hiki ke komo i luna (ANO): Nā kikoʻī hydrophobic vs. polar surface exposure.

Pills 3: Kemimi a me ka hoʻopaʻa ʻana

  • Hoʻololi Terminal: E wehewehe pono i ka hoʻopaʻa ʻana o N-terminal (e.g., amine manuahi, Acetylation, Pyroglutamate) a me C-terminal capping (e.g., ʻakika manuahi, Amidation).
  • Cyclization Architecture: E wehewehe pono i nā loulou atom no nā peptides cyclic—poʻo-a-huelo amide paʻa, kaulahao ʻaoʻao a hiki i nā alahaka lactam ʻaoʻao, a i ʻole nā ​​pālua cysteine ​​disulfide.
  • Koena Kanonical ʻAʻole: E wehewehe i nā ʻakika D-amino a pau, nā ʻakika β-amino, N-methylated koena, a i ʻole nā ​​hoʻololi ma hope o ka unuhi ʻana (e.g., lipidation, phosphorylation, PEGylation).

Pills 4: Nā kikoʻī kikoʻī a me ka laulā noi

  • Pono Ka Maemae: ʻAʻole, ≥85% (ka nānā ʻana), ≥95% (in vitro bioassays), aiʻole ≥98% (ola / Nā haʻawina hoʻonaʻauao IND).
  • Ka heluna nui: ʻO ka unahi miligrama (1-10 mg no ka nānā ʻana i ka paʻa mua) a hiki i ka pālākiō gram/kilo (hana hoʻokele).
  • Nā Koina Hoʻomaʻemaʻe: E wehewehe inā pono e hana ʻia ka mea ma ka Papa 100 nā lumi hoʻomaʻemaʻe e pale ai i ka endotoxin a me ka bioburden contamination i ka wā o ka hoʻāʻo ʻana i ka cell-based assays.

Nā papahana hoʻouna i hoʻouna ʻia

E hoʻomāmā i ka lawe ʻana i nā kikohoʻe, hoʻomākaukau i ka ʻikepili i ʻekolu mau ʻano maʻamau:

Pehea e hoʻouna ai i nā Peptides i hoʻolālā ʻia e AI i kahi CDMO: Handoff Playbook
Hōʻano waihona Maʻiʻo ʻike mua Ke kumu hana CDMO
KA hookeai / Kikokikona Hoʻokahi-hua helu AA, ID kaʻina, hoʻololi terminal ʻO ka parser kaʻina automate mua a me ka hōʻoia lōʻihi
PDB / mmCIF 3D koina atomika, iwi kuamoʻo dihedral, nā loulou disulfide Hoʻonohonoho hoʻonohonoho, 3D hōʻoia hoʻopaʻa ʻia
Uku JSON Ke kumu hoʻohālike, pLDDT/pAE pūʻulu, helu ʻia GRAVY, pI, kikoʻī kikoʻī Hoʻokomo papahana i loko o nā ʻōnaehana waiwai ʻoihana CDMO
CSV / Pūʻulu TSV Papaaina moho lehulehu (ID, kaʻina, ka maemae, unahi, N-manawa, C-manawa, hoʻololi) Kiʻekiʻe-throughput synthesis hana kauoha pūʻulu hana

No ke kōkua: Hoʻokomo mau i kahi faila hoʻonohonoho 3D (.pdb a i ʻole .cif) me nā laina laina no nā peptides cyclic a i ʻole multi-disulfide. Hoʻohana ka poʻe parsers CDMO automated i nā faila 3D e hōʻoia i nā palapala hoʻohui cysteine ​​ma mua o ke koho ʻana i ka resin kākoʻo paʻa.


2. Pre-Synthesis In Silico Triage Filters

ʻO nā hiʻohiʻona generative ka mea nui no ka pili paʻa paʻa. I ka hana ana pela, Hoʻopuka pinepine lākou i nā kaʻina hana kino ʻole i hiki ʻole a paʻakikī paha ke synthesize. Ma mua o ka hoʻopuka ʻana i kahi kauoha kūʻai, holo i nā moho ma o ka multi-parameter in silico screening cascade.

Wai Puka AI Raw (10,000 Na moho)

Kānana 1: GRAVY Hydropathicity (-0.5 i +0.2) Kānana Kānana 2: Uku Uuna & pI (|Uku Uuna| ≥ 2 ma ka pH 7.4) Kānana Kānana 3: CamSol Intrinsic Solubility Score (> -1.0) Kānana Kānana 4: TANGO β-Sheet Aggregation Propensity (< 5%) Holo i ka loko o ka moho hoʻomākaukau ʻana (100 Kiʻekiʻe-Hanaki Hits)

1. KAHUA (Awelika Nui o ka Hydropathicity)

Hoʻohālikelike ka helu GRAVY i ka huina o nā waiwai hydropathicity o nā waikawa amino āpau i puʻunaue ʻia e ka lōʻihi o ke kaʻina..

  • Laulā ʻoi loa: -0.5 i +0.2.
  • Paepae Pilikia Kiʻekiʻe: He nui nā helu +0.4 hōʻike i ka hydrophobicity koʻikoʻi. Hoʻopili kēia mau peptides i ka resin i ka wā SPPS a hōʻike i ka solubility wai ʻole..

2. Lae Isoelectric (pI) a me ka Uku Uuna

Lawe ʻo Peptides i ka uku ʻupena liʻiliʻi kokoke i kā lākou pI, e alakaʻi ana i ka pilina pilikino a me ka ua.

  • Rula: E helu i ka uku ma ka pH physiological (pH 7.4). E hōʻoia i ka uku ʻupena o ka liʻiliʻi +2 a i ʻole -2. Inā ʻo ka uku ʻupena ma waena -1 a +1 a aia i loko o ke kaʻina nā ʻāpana hydrophobic, e hoʻokomo i nā lysines solubilizing a i ʻole glutamate ma ka palena paʻa ʻole (e.g., hoʻohui i kahi hōʻailona KDK a i ʻole EEE).

3. CamSol Intrinsic Solubility Score

Nānā ʻo CamSol i ka waika amino acid hydrophobicity, uku, a me ka makemake o ka hale lua.

  • Paepae: Hōʻike nā helu maikaʻi i ka solubility intrinsic kiʻekiʻe. Ka helu helu ma lalo nei -1.0 pono e hōʻailona ʻia no ka loiloi kaʻina a i ʻole nā ​​lima hoʻoheheʻe kūikawā.

4. TANGO Huihui Propensity

Hoʻopili ʻo TANGO i ka makemake o nā ʻāpana peptide i wehe ʻia e hana i nā hui β-pepa intermolecular..

  • Paepae: ʻO kēlā me kēia ʻāpana kaʻina e hōʻike ana i kahi helu hōʻuluʻulu TANGO > 5% hōʻike i kahi pilikia nui no ka hoʻohui ʻana i ka resin i ka wā e hoʻolōʻihi ʻia ai ke kaulahao.

5. Nānā Motif Sequence

E hōʻailona a hoʻololi i nā kumu hoʻohālike pilikia ma mua o ka waiho ʻana:

  • Holo Holoi Hydrophobic: $> 3$ nā koena hydrophobic (e.g., Keena makaikai, LLL, FIW, IYF) hoʻoulu i ka hoʻopaʻa ʻana o ka β-pepa wikiwiki.
  • ʻO Aspartimide-Prone Dipeptides: DG, DS, A ME, a me nā kumu DN ma lalo o nā kūlana deprotection Fmoc maʻamau e hele i ka cyclization ʻaoʻao-chain e hana i nā huahana aspartimide.
  • Nā Pūʻulu Cysteine ​​lehulehu: Ua hoʻokaʻawale ʻia nā cysteinees i pale ʻole ʻia e ka liʻiliʻi 2 paʻakikī nā amino acids i ka wehe ʻana i ka hui palekana.

Ka Hoʻomākaʻikaʻi Pre-Synthesis Framework

Metric Triage Kaʻahele E akahele / Kaulana Warn hāʻule / Hoʻolālā hou Pilikia Hoʻolele Kumu
GRAVY Index -0.5 i +0.2 +0.2 i +0.4 $> +0.4$ ʻO ka hui ʻana ma ka resin, hiki ʻole ke hoʻoheheʻe wai
Uku Uuna (pH 7.4) Hoʻopiʻi ≥ 2
Helu CamSol $> 0.0$ $0.0$ i -1.0 $< -1.0$ Haʻahaʻa kinetic solubility, ka ua
Helu TANGO < 1% 1% i 5% > 5% β-pepa hoʻopaʻa, hoʻopili piha ʻole
Holo wailele ≤ 2 huikau $3$ huikau $> 3$ huikau ʻO ka ʻoki ʻana a me ka holoi ʻana i nā mea haumia

3. Nā ʻāpana pilikia koʻikoʻi: Ma kahi o AI Peptide Hits Fail on the Bench

ʻO ka hoʻokō synthetic ka unuhi ʻana i nā hiʻohiʻona kikohoʻe i mea kino. ʻO ka hoʻomaopopo ʻana i ke kemika kino kumu o SPPS hiki iā R&ʻO nā hui D e manaʻo i nā bottlenecks CDMO a hoʻomohala pū i nā hoʻolālā hoʻēmi pilikia.

Ki Takeaway: Pau 70% o AI-designed peptide synthesis fails mai ka on-resin inter-chain aggregation. Nā kumu hoʻohālike generative over-index ma ka hydrophobic packing e hoʻonui i ka ikehu paʻa i wānana ʻia, me ka hana ʻole ʻana i nā kaʻina e hōʻuluʻulu iā ia iho i loko o nā β-pepa hiki ʻole ke hoʻoheheʻe ʻia i ka wā paʻa-phase synthesis..

Pilikia 1: ʻO ka hoʻohui ʻana ma ka Resin a me ka hoʻopili ʻole ʻana

I ka wā SPPS, ʻO nā kaulahao peptide ulu e pili ana i ka resin kākoʻo paʻa hiki ke hana i waena- a me nā pepa β i hoʻopaʻa ʻia i ka hydrogen intramolecular. Wahi a nā mea i hala iho nei ma-resin β-pepa aggregation haʻawina, ʻO ka haku mele hydrophobic amino acid e alakaʻi pololei i ka hiolo ʻana o ka hale lua i loko o nā pores resin.

Hoʻopili kēia hōʻuluʻulu ʻana i ka pehu ʻana o ka solvent a hoʻopaʻa i ke komo ʻana o ka piperidine reagent i ka hui N-terminal Fmoc.. ʻO ka hopena:

  1. Hoʻolohi ka Fmoc Deprotection Kinetics: ʻO nā pōʻai hoʻopalekana e hana mau 3 hoʻonui i nā minuke 30+ minuke a hāʻule hapa paha.
  2. Hoʻohui ʻia nā Kaʻina Holoi: Noho mau pūʻulu amino unreacted i ka wā o ka hoʻohui ʻana, e hāʻawi ana i nā huila paʻakikī o N-1 a me N-2 holoi ʻana i nā haumia i aneane hiki ʻole ke hoʻokaʻawale ʻia e ka HPLC hoʻohuli..

Nānā Papa: I nā holo kiʻekiʻe-throughput synthesis o AI-hoʻokumu ʻia nā mea hoʻopaʻa me ka hydrophobic stretch (>3 nā koena hydrophobic), Hōʻike pinepine ka nānā ʻana o UV deprotection Fmoc i ka hāʻule ʻana o ka pono ma hope o ke koena 8-12. ʻO ka hoʻokomo ʻana i nā pseudoproline dipeptides ma kēia mau kūlana e hoʻihoʻi i nā kinetics reaction baseline a hoʻopau i nā haumia holoi ʻoki ʻia..

Mokuʻāina Resin Hui:

[ʻO Resin Bead] (Hydrophobic β-Pepa Hoʻopaʻa) Fmoc-Amine (Kāohi ʻia) x (ʻAʻole hiki ke loaʻa iā Piperidine)

Hoʻoholo ʻia / Mokuʻāina Hoʻopilikia ʻia:

[ʻO Resin Bead] [Pseudoproline / Isoacyl Handle] Fmoc-Amine (Hōʻike ʻia) ► (Hoʻopau hoʻopau)

Pilikia 2: Racemization i ka wā hui

ʻAʻole helu nā kumu hoʻohālike AI no ke kūpaʻa stereochemical i ka wā o ka hoʻāla ʻana. ʻO ka SPPS i kōkua ʻia i ka microwave kiʻekiʻe e hoʻolalelale i ka hoʻohui ʻana akā hoʻonui nui i nā pilikia racemization no nā waikawa amino kikoʻī.:

  • Cysteine: Hiki ke maʻalahi i ka base-catalyzed α-carbon racemization ma o ka enolization i ka wā o ka hoʻoulu ʻana i ka carbodiimide.
  • Histidine: ʻO ke kaulahao ʻaoʻao imidazole ke komo i ka catalysis base intramolecular, alakaʻi i ka L-to-D stereoisomerization.
  • Aspartate: Hoʻoikaika ka hoʻoulu ʻana i ka base-mediated i ka hoʻokumu ʻana o D-aspartate me ka hoʻonohonoho hou ʻana o aspartimide.

Pilikia 3: ʻO ka ʻaoʻao ʻaoʻao o ka ʻaoʻao ʻaoʻao ʻo TFA

Hoʻopau ka honua me ka hoʻohana ʻana i ka Trifluoroacetic Acid (TFA) hoʻokuʻu i nā carbocation reactive mai nā hui pale kaulahao ʻaoʻao (e.g., tBu, Ua haʻi ʻo Trt, Pbf). I nā kaʻina waiwai i Tryptophan, Tirosine, a i ʻole Methionine:

  • Hoʻopili hou nā carbocation manuahi i ke apo indole o Trp a i ʻole ka thioether o Met.
  • ʻAʻole lawa ka cocktails scavenger (EDT, TIS, wai, phenol) alakaʻi i nā huahana ʻaoʻao alkylated hiki ʻole ke hoʻohaumia i ka huahana hope.

Pilikia 4: ʻO ka hui ʻana o Disulfide a me ka Ambiguity

De novo peptides i hana ʻia me 2, 4, a i ʻole 6 ʻO nā koena cysteine ​​e hōʻike nei i nā pilikia nui o ka pelu. ʻO ka hoʻoheheʻe ʻia ʻana o ka ea o kahi peptide 4-cysteine ​​​​hiki ke hana i ʻekolu regioisomers disulfide.:

Kaulike (Cys_1-Cys_2, Cys_3-Cys_4) vs. Kūlike-Parallel (Cys_1-Cys_4, Cys_2-Cys_3) vs. Hoʻopili ʻia (Cys_1-Cys_3, Cys_2-Cys_4)

Inā manaʻo kekahi kumu hoʻohālike AI i kahi paʻi maoli, ʻO ka hoʻoheheʻe ʻana i ka ea maʻalahi i DMSO/wai e hāʻawi pinepine i nā isomers topological ʻole a i ʻole nā ​​oligomers soluble..

Pilikia 5: Ka Manaʻo Kūkākūkā i loko o ka HPLC Hoʻololi

Hāʻawi pinepine ka Hydrophobic AI i ka laulā, mokuahana, a i ʻole nā ​​piko huelo ma nā kolamu HPLC analytical maʻamau C18. Loaʻa kēia hoʻonui nui no ka mea aia ka peptide ma ke ʻano he nui o nā conformers hoʻololi mālie i ka pae kelepona, a i ʻole no ka hui ʻana o ke kaʻina hydrophobic ma ke kolamu kū. Me ka ʻole o ka spectrometry nuipa orthogonal, Hoʻomaopopo pinepine ʻia kēia mau puʻupuʻu i hoʻokaʻawale ʻia ma ke ʻano he synthesis failure ma mua o ka hoʻohuli ʻana i ka conformational equilibria..


4. Manaʻo ʻia nā kuʻina hōʻoia: Hoʻopau i ka hoʻoweliweli AI-i-Bench Handoffs

E hoʻopaʻa i nā wānana helu me nā mea hoʻopuka kino, Pono nā CDMO e hoʻohana i nā loea synthetic kūikawā a me nā suites hōʻike analytical.

Hoʻokomo ʻia ke kaʻina o AI

Hiki i ka CDMO ke hō'ike mua i ka pilikia o ka hui 'ana? ► Hoʻohui i nā Pseudoprolines / Palapala 'Isoacyl Peptides Multi-Disulfide? ► Nā Pūʻulu Hoʻomalu Orthogonal (Trt/Acm/Mmt) Hydrophobicity kiʻekiʻe? ► PEGylated Solubilizing Handles Synthesis & I-Line Process Analytical Technology (PAT) ʻO ka manawa maoli ʻo Fmoc Deprotection UV Monitoring Micro-Cleavage LC-MS Inter-Step Checks Orthogonal Analytical Characterization Suite

  1. RP-HPLC & ESI-MS / MALDI-TOF (Mass & Maemae)
  2. Dichroism pōʻai (CD) ʻIkepili (Hoʻolālā ʻelua)
  3. Hoʻopuʻi ʻana i ka māmā (DLS) (Monomeric Verification)
  4. ʻO Ellman's Assay & Ellman-LC-MS (ʻO ka hui ʻana o Disulfide)

Nā Kūlana Kūlana Kiʻekiʻe no nā Kaʻina AI "Paʻakikī".

Ke hoʻāla ʻia kahi kaʻina hana AI i nā paepae makaʻala i ka wā pre-synthesis triage, Hoʻolālā nā CDMO akamai i nā hoʻolālā kemika i hoʻohālikelike ʻia:

  1. Pseudoproline Dipeptides: Hookomo X aa-Ser, X aa-Thr, a i ʻole X aa-Cys oxazolidine dipeptides i kēlā me kēia 5-6 koena e hoʻopau i ka hana kiʻekiʻe β-sheet i ka wā e hoʻolōʻihi ʻia ai ka resin..
  2. Isoacyl Peptide Technology: Hoʻololi manawaleʻa i nā paʻa peptide i nā loulou ester (O-N acyl hoʻololi). Hoʻokaʻawale ka loulou ester i ka hoʻopaʻa ʻana o ka β-pepa i ka wā synthesis; ka ʻike ʻana i ka pH neutral 7.4 hoʻomaka wikiwiki ka buffer, ka nui O-to-N acyl migration e hoʻihoʻi i ka iwi kuamoʻo amide.
  3. Nā Pūʻulu Hoʻomalu Disulfide Orthogonal: E hoʻohana i nā hui pale orthogonal—e like me Trityl (Ua haʻi ʻo Trt), Acetamidomethyl (Acm), a me Monomethoxytriyl (Mmt)—e hooikaika stepwise, kuhikuhi ʻia i ka hoʻokumu ʻana i nā mea paʻa disulfide ma mua o ka hilinaʻi ʻana i ka thermodynamic air oxidation.
  4. Pre-Synthesis Aggregation Predictive Modeling: Hoʻohana nā CDMO kiʻekiʻe pre-synthesis aggregation predictive models e hoʻonui i ka nui o ka hoʻouka resin, koho i nā resins PEG hoʻouka haʻahaʻa (e.g., ChemMatrix), a hoʻololi i nā mahana kahe-synthesis me ka ikaika.

ʻO ka Hui Hoʻopaʻa Analytical Orthogonal

Hōʻoia hōʻoia ʻenehana Analytical Pahu Hoʻopono / Koina ʻae Waiwai Hana
Maemae & ʻIkepili Nui RP-HPLC (C18/C4) + ESI-MS / MALDI-TOF ʻO ka piko nui hoʻokahi; maʻemaʻe pahuhopu ≥ 95% aiʻole ≥ 98%; monoisotopic mass i loko o ± 0.5 A E hōʻoia i ka ʻike o ke kaʻina holoʻokoʻa a me ka ʻole o nā kaʻina holoi
Hoʻolālā ʻelua Dichroism pōʻai (CD) ʻIkepili Kikoʻo mamao-UV (190–260 nm) hoʻohālikelike i ka α-helix i wānana ʻia (208/222 nm minima) a i ʻole β-pepa (218 nm liʻiliʻi) E hōʻoia i ka hoʻopili ʻana i ka peptide kino e like me ke kumu hoʻohālike 3D
Mokuʻāina Huihui Hoʻopuʻi ʻana i ka māmā (DLS) / SEC-MALS ʻO ka radius hydrodynamic (Rₕ) pili i ka mokuʻāina monomeric; helu helu polydispersity (PDI) $< 0.15$ E hōʻoia i ka peptide ʻaʻole i hoʻohui ʻia ma mua o ka hoʻopaʻa ʻana i ka cell-based a i ʻole biophysical binding assays
Hoʻohui Disulfide ʻO Ellman's Assay (DTNB) + LC-MS/MS palapala palapala Maʻiʻo thiol manuahi < 0.05 mol SH/mol peptide; ʻAʻohe ʻāpana ʻiona no nā pālua Cys-Cys E hōʻoia i ka hoʻonaʻauao piha a me ka hoʻoponopono ʻana i ka topology pairing disulfide

5. ʻO ka puke pāʻani hana: Ke hoʻokō nei i nā Handoff CDMO holomua

No ka hoʻokō ʻana i ka waiho ʻana o AI peptide, R&Pono nā hui D e hoʻokumu i kahi kaila hana lima ʻanuʻu maʻamau.

ʻanuʻu 1: Hoʻokuʻu aku i ka pūʻolo hoʻolālā helu helu (PDB, KA hookeai, JSON, Heluhelu)

ʻanuʻu 2: E noi i loko o ke kānana ʻo Silicon Triage (KAHUA, pI, CamSol, TANGO) ʻanuʻu 3: ʻO ka hoʻopaʻa ʻana ma mua o ka CDMO & KaʻAnuʻu Hana Manaʻo 4: Hoʻolālikelike hoʻokele & Kaʻina Hana Analytical Control Step 5: Hoʻokuʻu ʻIkepili piha & QC palapala hōʻoia

ʻanuʻu 1: E hoʻokuʻu aku i ka pūʻolo hoʻolālā kikohoʻe piha

E hōʻuluʻulu i nā hoʻopuka helu helu āpau—me nā faila hoʻonohonoho PDB, Nā kaʻina FASTA, kumu hoʻohālike JSONs, a me ke koena pLDDT arrays—i loko o ka waihona hoʻouna hoʻokahi.

ʻanuʻu 2: E hoʻokō i ka nānā ʻana i ka hoʻāʻo ʻana i ka Silicon Triage

E kānana i nā moho me ka hoʻohana ʻana iā GRAVY, pI, CamSol, a me TANGO lula. Hoʻopau i nā outliers non-synthesizable a hōʻike i nā moho palena palena me nā hoʻololi kemika i noi ʻia (e.g., hōʻailona hoʻoheheʻe, N-terminal acetylation).

ʻanuʻu 3: ʻO ka loiloi kūpono a me ka hoʻolālā kemika CDMO

E hoʻouna i ka pūʻolo kānana i kāu hoa CDMO. Hōʻike ka hui ʻenekinia synthesis CDMO:

  • Koho resin (Polystyrene vs. PEG-ChemMatrix).
  • Hoʻohui kemika (KA HANAU, DIC/Oxyma, a i ʻole PyBOP).
  • Hoʻolālā pale no nā kumu paʻakikī.

ʻanuʻu 4: Hoʻohui ʻia ʻo Pilot Scale me nā Mana Kaʻina

No nā scaffolds novel de novo, e hoʻokō i kahi hoʻonohonoho hoʻokele liʻiliʻi (1–5 mg) e hōʻike ana i ka nānā ʻana o UV i ka manawa maoli o Fmoc deprotection kinetics a me ka micro-cleavage LC-MS analysis ma mua o ka hana nui..

ʻanuʻu 5: Hoʻokuʻu ʻia QC Analytical a me ka Packroom Cleanroom

E hōʻoia i nā mea hope e pili ana i ka hui hōʻoia orthogonal. E hōʻoia i ka hoʻomaʻemaʻe ʻia ʻana o nā peptides i manaʻo ʻia no ka moʻomeheu cell a i ʻole nā ​​hiʻohiʻona preclinical i ka papa 100 nā kaiapuni ultra-sterile e hōʻoiaʻiʻo i ka pau ʻole o ka endotoxin.


Ka hui pū ʻana me nā CDMO kūikawā no AI-Designed Peptides

Ke hoʻomau nei nā hiʻohiʻona AI generative e hoʻonui i ka ʻāina hoʻolālā o nā peptides therapeutic, ʻO ka hopena e pili ana i ka hoʻokō kino o ke kemika synthetic. ʻOiai ke mālama nei nā mea hoʻolako generalist i nā peptides maʻamau e like me nā mea kikoʻī, Ua koi ʻo complex AI i kahi hoa CDMO kūikawā i lako me nā ʻenehana synthesis holomua, pre-synthesis feasibility kānana, a me nā mana maikaʻi ikaika.

Ke koho ʻana i kahi hoa hana hana no nā kaʻina i hoʻolālā ʻia AI, ka loiloi ʻana i nā mea hiki ke kahua—e like me ke komo ʻana i nā suites hoʻololi nui, nā lumi hoʻomaʻemaʻe ultra-sterile, a me nā koho hoʻonui maʻalahi—e hōʻoia i ka hoʻololi pono ʻana o nā hoʻolālā helu i ka hōʻoia kino.. R&Hiki i nā hui D e ʻimi ana e hoʻopili i ka hoʻolālā kikohoʻe me ka hoʻokō ʻana o ka hale hana ke kūkākūkā i nā paepae kūikawā e like me MOL Changes for nā lawelawe hana peptide synthesis maʻamau a me nā loiloi kūpono ʻenehana i hoʻohālikelike ʻia i ka hoʻopau ʻana i ka hoʻopiʻi AI-to-bench handoff.

Hōʻoia kūpono ʻenehana: No ka loiloi ʻana i kāu kōpili moho helu e pili ana i nā ʻāpana hiki ke hana synthesis, e kūkākūkā me ka hui ʻenehana MOL Changes no ka loiloi pre-synthesis piha.

Xiaoxia Chen

Xiaoxia Chen

Laau Laau Hou R&D ʻenehana Kaʻike kumu: Loaʻa ka pahuhopu, pilina hana-hana (SAR) kālailai, peptide-lāʻau conjugates (Nā PDC), a me ka hoʻomohala ʻana i nā peptides anti-kahiko a me ka metabolic.

Pilikino: Ua alakaʻi ʻo Xiaoxia Chen i ka ʻike mua ʻana a me ka noiʻi preclinical no kekahi mau lāʻau peptide metabolic a me ka tumor-targeted.. ʻAʻole wale ʻo ia i mākaukau i ka nānā ʻana i nā hale waihona puke peptide, akā akamai nō hoʻi i ka hoʻohana ʻana i ka biology computational kōkua AI no ka hoʻolālā ʻana o ka de novo peptide sequence.. I kēia manawa, ke alakaʻi nei ʻo ia i kahi hui i hoʻolaʻa ʻia i ka noiʻi hohonu a me ka hoʻomohala ʻana o nā agonists multifunctional hanauna hou (like me pālua- a i ʻole nā ​​peptides hoʻohaʻahaʻa momona ʻekolu) a me nā peptides hoʻoponopono hou i ke kino.

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana